SCHEMBL19481798

SCHEMBL19481798

O=C(C1CC(F)C1)N1CCN(c2ccnn3cc(-c4ccc(N5CCNCC5)cc4)cc23)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMP4 P12644 2/20 0.40
KHK P50053 3/20 0.40
RET P07949 2/20 0.39
ACVR1 Q04771 9/20 0.38
KDR P35968 3/20 0.38
TGFBR1 P36897 3/20 0.38
PRKAB1 Q9Y478 3/20 0.38
BMPR1B O00238 8/20 0.37
ACVRL1 P37023 8/20 0.37
BMPR1A P36894 6/20 0.37
RUVBL1 Q9Y265 1/20 0.37
MAPT P10636 1/20 0.37
ACVR1B P36896 6/20 0.37
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TGFBR2 P37173 2/20 0.36
BMPR2 Q13873 2/20 0.36
RIPK2 O43353 1/20 0.36
ACVR2A P27037 1/20 0.36
ACVR2B Q13705 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19458948 0.91 TDP1 (0.45) BMP4KHKRETACVR1KDR
SCHEMBL19481735 0.90 BMP4 (0.41) BMP4KHKRETACVR1KDR
SCHEMBL25766071 0.90 BMP4 (0.41) BMP4KHKRETACVR1KDR
SCHEMBL19481737 0.90 BMP4 (0.41) BMP4KHKRETACVR1KDR
SCHEMBL19481702 0.89 MAPT (0.44) BMP4KHKRETACVR1KDR
SCHEMBL25155062 0.89 RET (0.39) BMP4KHKRETACVR1KDR
SCHEMBL19481840 0.89 BMP4 (0.40) BMP4KHKRETACVR1KDR
SCHEMBL19481915 0.84 RET (0.41) BMP4KHKRETACVR1KDR
SCHEMBL25795703 0.84 RET (0.41) BMP4KHKRETACVR1KDR
SCHEMBL19481708 0.81 RUVBL1 (0.45) RUVBL1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 EP disclosed
US-11634422-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2023-04-25 US disclosed
US-10669277-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2020-06-02 US disclosed
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2020-01-30 US disclosed
US-10233186-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2019-03-19 US disclosed
WO-2017181117-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2017-10-19 WO disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 US disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669277-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 BMP4 21/4885KHK 2037/4885RET 50/4885
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 BMP4 21/4885KHK 2037/4885RET 50/4885
US-11634422-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 BMP4 21/4885KHK 2037/4885RET 50/4885
US-10233186-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 BMP4 22/4885KHK 2328/4885RET 56/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 BMP4 21/4885KHK 2037/4885RET 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.